Pro-Dex, Inc.

Pro-Dex, Inc.

NNASDAQ:PDEX
63.44
USD
+3.20
(+5.31%)
3.65EPS
18.42P/E
221.03MMarket Cap
Feb 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
3.1
3.21
4.63
5.43
5.22
6.48
8.91
10.02
11.56
12.91
15.39
20.25
24.04
24.78
Basic EPS, GAAP
-0.14
-0.09
0.2
1.26
0.38
0.99
1.56
1.63
1.26
1.98
0.61
2.73
4.24
3.75
Free Cash Flow per Basic Share
-0.14
-0.26
0.03
0.64
0.5
0.46
1.12
-2.74
-0.69
1.26
1.5
-0.89
2.1
3.33
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.19
2.05
2.19
3.41
3.99
4.21
5
5.51
7.07
8.91
9.18
11.23
14.95
15.4
Tangible Book Value per Share
2.16
1.83
2.05
3.37
3.96
4.18
4.96
5.46
7.04
8.89
9.16
11.23
12.69
13.16
Basic Weighted Avg Shares
3
4
4
4
4
4
4
4
4
4
3
3
3
3
Sales/Revenue/Turnover
11
13
19
22
22
27
35
38
42
46
54
67
78
80
Operating Margin (%)
-7.53
-6.74
5.48
12.97
15.16
18.37
20.27
11.9
12.27
12.5
13.32
16.05
16.75
16.84
Depreciation Expense
1
1
1
1
1
- -
1
1
1
1
1
1
1
1
Net Income, GAAP
- -
- -
1
5
2
4
6
6
5
7
2
9
14
12
Effective Tax Rate (%)
- -
- -
2.22
- -
37.89
23.85
22.65
18.99
19.7
24.97
19.25
25.54
24.16
20.71
Profit Margin (%)
-4.51
-2.73
4.28
23.17
7.22
15.27
17.55
16.22
10.88
15.35
3.95
13.48
17.62
15.12
Working Capital
7
5
7
10
14
17
17
19
20
21
24
33
40
41
LT Debt
- -
- -
- -
- -
- -
4
6
14
12
11
9
10
14
14
Total Equity
9
8
9
14
17
17
19
20
25
32
31
37
48
49
Return on Invested Capital (%)
- -
- -
9.03
- -
9.51
19.52
22.94
11.81
10.55
9.74
12.61
16.17
16.45
17.16
Return on Capital (%)
- -
- -
9.79
- -
10.44
22.2
26.42
20.92
12.84
17.03
5.68
19.66
23.84
20.65
Return on Common Equity (%)
-5.69
-4.13
9.47
45.02
10.46
24.2
33.89
31.52
20.09
24.81
6.81
26.6
32.43
26.48

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
ST Debt
4
5
4
LT Borrowings
14
13
12
LT Finance Leases
1
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
157
187
221

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
Total Current Assets
54
53
54
Cash, Cash Equivalents & STI
11
9
13
Accounts Receivable, Net
19
21
18
Inventories
22
21
22
Total Current Liabilities
15
13
13
Payables & Accruals
10
8
9
ST Debt
4
5
4
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.36%
19.45%
30.03%
Free Cash Flow
82.11%
-164.78%
-330.84%
Net Income, GAAP
98.77%
66.63%
52.17%
Sales/Revenue/Turnover
15.22%
15.43%
16.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
15
17
17
17
67
2026
19
19
20
20
78
2027
21
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.76
0.63
1
0.37
2.73
2026
1.43
0.67
1.23
0.9
4.24
2027
0.95
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Richard Lee van Kirk
Full Time Employees
206
Sector
Health technology
Industry
Medical specialties
Address
2361 McGaw Avenue Irvine CA United States 92614
IPO Date
May 31, 1994
Business
Pro-Dex, Inc. (NasdaqGS:PDEX) designs, develops, manufactures and sells powered surgical instruments primarily for medical device original equipment manufacturers worldwide; offers autoclavable, battery-powered and electric multi-function surgical drivers and shavers used in orthopedic, thoracic and craniomaxillofacial markets, as well as rotary air motors for medical, aerospace, industrial automation and other industries; and provides engineering, quality, regulatory consulting, contract manufacturing, assembly, testing and prototyping services to hospitals, medical engineering labs, scientific research facilities and high-tech manufacturing operations. The company operates from ISO 13485-certified facilities in Irvine and Tustin, California, serving customers including leading providers of medical, dental, neurosurgery, spine, energy, aerospace and defense products. Founded in 1978 and headquartered at 2361 McGaw Avenue, Irvine, California 92614, Pro-Dex maintains full vertical integration from 510(k) filings and precision machining to product engineering and compliance management. In fiscal 2025, net sales increased 17% to $53.8 million driven by higher-margin next-generation handpieces and repair services, with gross margins expanding despite a transition to multiple-facility operations; fiscal 2026 first-quarter net sales rose 24% to $18.5 million; and the company hired a new Director of Operations to support ongoing expansion while shipping production volumes of advanced surgical handpieces.

Company News

  • Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Surpass Estimates

  • ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?

  • Pro-Dex (NASDAQ:PDEX) Stock Breaks Below Two Hundred Day Moving Average – What’s Next?

  • 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

  • Best Momentum Stocks to Buy for September 18th

  • New Strong Buy Stocks for September 18th

  • Bank of New York Mellon Corp Invests $678,000 in Pro-Dex, Inc. $PDEX

  • Pro-Dex: Still A Buy, But Don't Chase

  • Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results

  • Pro-Dex (NASDAQ:PDEX) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

  • Pro-Dex, Inc. Announces Acquisition of Advanced Precision Machining

  • Pro-Dex, Inc. Announces Fiscal 2026 Second Quarter and Six-Month Results

  • Head-To-Head Contrast: Pro-Dex (NASDAQ:PDEX) vs. STAAR Surgical (NASDAQ:STAA)

  • Pro-Dex: A Niche Surgical Tools Microcap Trading At A Discount

  • D.A. Davidson & CO. Increases Holdings in Pro-Dex, Inc. $PDEX

  • Pro-Dex Valuation Is Attractive Despite Customer Risk

  • Head to Head Survey: Cardinal Health (NYSE:CAH) vs. Pro-Dex (NASDAQ:PDEX)

  • Head-To-Head Review: Pro-Dex (NASDAQ:PDEX) & Spotlight Innovation (OTCMKTS:STLT)

  • Pro-Dex, Inc. Announces Contract Extension With Largest Customer

  • Head to Head Contrast: Spotlight Innovation (OTCMKTS:STLT) versus Pro-Dex (NASDAQ:PDEX)